Quote this publication Share Print

REVOLADE (eltrombopag), thrombopoietin receptor agonist

HAEMATOLOGY - New indication
Opinions on drugs - Posted on Nov 10 2016

Reason for request

Extension of indication

Minor improvement in the treatment of acquired severe aplastic anaemia refractory and ineligible for stem-cell transplantation

  • REVOLADE now has Marketing Authorisation in the treatment of adults with acquired severe aplastic anaemia who are either refractory to prior immunosuppressive therapy or heavily pretreated and who are ineligible for haematopoietic stem-cell transplantation.
  • In the absence of survival data, this treatment is non-curative. It does nevertheless represent a minor improvement in treatment this new indication.


Clinical Benefit



Clinical Added Value



Therapeutic use


Contact Us

Évaluation des médicaments